A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

When surveyed, many physicians said the belief that patients had adequate symptom control was why they didn’t add more meds.

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Law enforcement agencies around Troup County are rallying behind one of their own in order to help a local state trooper who ...

Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Tectonic Therapeutics Inc. (TECX) announced favorable Phase 1a topline data for its lead asset, TX45, a long-acting, potentially ...

Edgewise's lead drug, Sevasemten, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...